

## **Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1**

Pragya D. Yadav<sup>1#\*</sup>, Ph.D, Gajanan N. Sapkal<sup>1#</sup>, Ph.D, Priya Abraham<sup>1</sup>, M.D, Ph.D, Gururaj Deshpande<sup>1</sup>, Ph.D, Dimpal A Nyayanit<sup>1</sup>, Ph.D, Deepak Y. Patil<sup>1</sup>, Ph.D, Nivedita Gupta<sup>2</sup>, Ph.D, Rima R. Sahay<sup>1</sup>, M.D, Anita M. Shete<sup>1</sup>, Ph.D, Sanjay Kumar<sup>3</sup>, M.Ch, Samiran Panda<sup>2</sup>, M.D., Ph.D, Balram Bhargava<sup>2</sup>, D.M.

# Equal first author

<sup>1</sup>Indian Council of Medical Research-National Institute of Virology, Pune, India

<sup>2</sup>Indian Council of Medical Research, V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi, India

<sup>3</sup>Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College (AFMC), Pune, Maharashtra, India

### **Corresponding author\*:**

Dr. Pragya D Yadav,  
Scientist 'E' and Group Leader,  
Maximum Containment Facility,  
Indian Council of Medical Research- National Institute of Virology,  
Sus Road, Pashan, Pune-411 021, India.  
Phone: +9120-260061111, Fax No. 91-20-26122669  
Email: hellopragya22@gmail.com

**Keywords:** Variant under investigation, B.1.617, neutralization, Covishield, SARS-CoV-2

**Running title:**Neutralization of B.1.617.1 with sera of Covishield vaccinees

**Abstract:**

Covishield comprises the larger proportion in the vaccination program in India. Hence, it is of utmost importance to understand neutralizing capability of vaccine against the B.1.617.1 variant which is considered to responsible for surge of the cases in India. The neutralizing-antibody (NAb) titer against B.1.617.1 and prototype B.1 variant (D614G) was determined of the vaccine sera (4 weeks after second dose) of COVID-19 naïve subjects (n=43) and COVID-19 recovered subjects (n=18). The results demonstrated that sera of COVID-19 recovered subjects (n=18) who received two doses of Covishield have higher NAb response compared to the COVID-19 naïve with a significant difference ( $p < 0.0001$ ) in NAb titer against B.1 and B.1.617.1 In spite of reduction in the neutralizing titer against B.1.617.1 variant; Covishield vaccine-induced antibodies are likely to be protective to limit the severity and mortality of the disease in the vaccinated individuals.

## Text

SARS-CoV-2 variants have emerged and spread to other countries during this pandemic [1]. Many of the studies have reported reduced neutralization capabilities of vaccines viz., mRNA-1273, NVX-CoV2373, BNT162b2, and ChAdOx1-nCoV19 against different variants B.1.1.7, B.1.351 and B.1.1.28 P1 [1-2]. Recently, SARS-CoV-2 variant, B.1.617.1, B.1.617.2 and B.1.617.3 with specific deleterious mutations have been reported from India [3-4], which has been associated with increase in the number of SARS-CoV-2 cases especially in Maharashtra state [3]. This variant has been shown to have higher transmissibility and pathogenicity in hamster model and has raised serious concern pertaining to the national COVID-19 vaccination program in India and other countries [3,5]. Over 177 million doses of vaccine have been administered to Indian citizens with two approved vaccines- Covishield (Astrazeneca-Oxford) and Covaxin™ (BBV152) [6]. Recently, we have demonstrated the neutralizing efficacy of Covaxin™ against B.1.617.1 variant [4,7,8]. Covishield comprises the larger proportion in the vaccination program in India. Hence, it is of utmost importance to understand neutralizing capability of Covishield vaccine against this emerging variant.

We have evaluated neutralizing capability of the Covishield vaccine recipient sera obtained four weeks after the second dose of COVID-19 naïve subjects (n=43) and COVID-19 positive recovered subjects (n=18).

The neutralizing-antibody (NAb) titer against B.1.167.1 and prototype B.1 variant (D614G) was determined for both the categories of sera. Of the sera obtained from COVID-19 naïve subjects, 23.25% samples (n=10) didn't show NAb titer against both the variants. 27.90% of the samples (n=12) showed NAb titer only with B.1. A total of 21

serum specimens (48.83%) elicited NAb titers against both B.1 and B.1.617.1 variants. The GMT along with standard deviation of Covishield vaccinee sera against B.1 and B.1.617.1 were  $42.92 \pm 3.8$  (95% CI:40.21-128.5; n=43) and  $21.92 \pm 4.42$  (95% CI:24.4-62.64; n=43) respectively.

The results demonstrated that sera of COVID-19 positive recovered subjects (n=18, red color) who received two doses of Covishield have higher antibody response compared to the COVID-19 naïve vaccinees (n=43, green color) with a significant difference ( $p < 0.0001$ ) in NAb titer against B.1 and B.1.617.1 variants (Figure 1 A and 1B). An increase in the GMT of the sera of COVID-19 recovered cases with vaccination (29.5 fold) compared to COVID-19 naïve vaccinees (23.5 fold) was observed against B.1 and B.1.617.1 respectively. This indicates that COVID-19 recovered cases vaccinated with 2 doses had very high immune response in comparison to COVID-19 naïve vaccinees who received 2 doses.

A pair-wise comparison using Wilcoxon matched-pairs signed-rank test demonstrated a significant two-fold reduction ( $p\text{-value} < 0.0001$ ) in the neutralization titer of B.1.617.1 compared to B.1 variant in the COVID-19 naïve vaccinees (Figure 1 C). Further, we also determined the IgG titer against S1-RBD and observed a non-significant difference between COVID-19 recovered cases administered with 2 dose of vaccine and COVID-19 naïve vaccinated subjects (Figure 1D).

In spite of reduction in the neutralizing titer against B.1.617.1 variant; Covishield vaccine-induced antibodies are likely to be protective in limiting the severity of disease and mortality in the vaccinated individuals. Also COVID-19 recovered individuals with immunization can maintain protective antibody titer for longer period.

## **Ethical approval**

The study was approved by the Institutional Biosafety Committee and Institutional Human Ethics Committee of ICMR-NIV, Pune, India under the project 'Propagation of new SARS-CoV-2 variant isolate and characterization in cell culture and animal model'.

## **Author Contributions**

PDY and PA contributed to study design, data analysis, interpretation and writing and critical review. GNS, GRD, DYP, RRS, AMS, DAN and SK contributed to data collection, interpretation, writing and critical review. NG, SP, and BB contributed to the critical review and finalization of the paper.

## **Conflicts of Interest**

Authors do not have a conflict of interest among themselves.

## **Financial support & sponsorship**

Financial support was provided by the Indian Council of Medical Research (ICMR), New Delhi at ICMR-National Institute of Virology, Pune under intramural funding 'COVID-19'.

## **Acknowledgement**

Authors gratefully acknowledge the staff of ICMR-NIV, Pune including Dr. Rajlaxmi Jain, Mr. Prasad Sarkale, Mr. Shrikant Baradkar, Ms. AashaSalunkhe and Mr. Chetan Patil for extending excellent technical support.

## **References**

1. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants—clinical, public health, and vaccine implications. *N Engl J Med* **2021**.
2. Garcia-Beltran WF, Lam EC, Denis KS, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell* **2021**.

3. Cherian S, Potdar V, Jadhav S, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. *bioRxiv* **2021**.
4. Yadav P, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. *Clin Infect Dis* **2021**; ciab411.
5. Yadav PD, Mohandas S, Shete AM, et al. SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant. *bioRxiv* **2021**.
6. COVID-19 vaccination. Available from: <https://www.mohfw.gov.in/>. Accessed on 13 May 2021.
7. Sapkal GN, Yadav PD, Ella R, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. *J Travel Med* **2021**; taab051.
8. Sapkal G, Yadav P, Ella R, et al. Neutralization of B.1.1. 28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine. *bioRxiv* **2021**.

### Figure legend

**Figure 1: Neutralization of B.1.617.1 variant:** Comparison of NAb titer between COVID-19 naïve cases (green, n=43) and COVID-19 recovered cases (red, n=18) administered with 2 doses of vaccine (sera collected 28 days after the second dose) against B.1 (**A**) and B.1.617.1 (**B**). A two-tailed pair-wise comparison was performed

using the Mann-Whitney test and \*\*\*\* represent p-value <0.001 **C)** Scatter plot depicting the neutralization activity of the COVID-19 naïve cases (n=43) vaccinated with two doses of Covishield vaccine ( sera collected 28 days after the second dose) against the prototype B.1 (D614G) (green, triangle) and B.1.617.1 (green, square). A neutralization reduction factor of 1.94 was observed between the B.1 (D614G) and B.1.617.1 variant. A two-tailed pair-wise comparison was performed using the Wilcoxon matched-pairs signed-rank test with a p-value of 0.05. \*\*\*\* represent p-value <0.001 and \*\*p value=0.0038, ns= non-significant p-value **(D)** A comparison of IgG antibody titer against RBD protein between COVID-19 naïve cases (n=43) and COVID-19 recovered cases (n=18) administered with 2 doses of vaccine. A two-tailed pair-wise comparison was performed using the Mann-Whitney test and ns= non-significant p-value.

